StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

Shares of NASDAQ:NERV opened at $2.51 on Thursday. Minerva Neurosciences has a 52-week low of $2.26 and a 52-week high of $13.49. The firm has a fifty day moving average of $2.70 and a 200 day moving average of $2.80. The firm has a market capitalization of $17.55 million, a PE ratio of -0.56 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, sell-side analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.